With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL ... medicine used to treat a disease called paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License ...

ASH 2024: Clinical Impact of Promising Treatments for PNH Dr Ilene Weitz reviews ... Medscape, December 31, 2024 Key Studies in Chronic Lymphocytic Leukemia From ASH 2024 Practice-changing studies ...

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH ...

Significant unmet need remains in PNH, a chronic, rare and potentially life-threatening blood disorder; a large proportion of patients can remain anemic and dependent on blood transfusions 3,4 ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...